Verastem, Inc.
VS-7375
multiple KRAS G12D solid tumors
Resolved
157days ago
Phase 1 readout · ~ Jan 31, 2026 estimated
What's at stake
Phase 1 trial results for VS-7375 in multiple KRAS G12D solid tumors are due ~ Jan 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Report an interim update on the Phase 1/2 trial of VS-7375 in 1H 2026.”